Quad Technologies Announces Poster Presentation at the 58th American Society of Hematology Annual Meeting

WOBURN, Mass.–(BUSINESS WIRE)–An abstract from Quad Technologies (”Quad”) has been accepted for presentation at the 58th annual American Society of Hematology meeting in San Diego, CA on December 3-6, 2016. The abstract is published on the ASH website at http://www.hematology.org/. In collaboration with an external partner focused on CAR-T cancer immunotherapy, the focus of the poster presentation is the use …

Quad Technologies Finalist for the 2016 BioProcess International Award

Quad Technologies has been nominated for a 2016 BioProcess International Award in the Emerging Company category.  Nominees in this category have been recognized for significant industry adoption with an opportunity to change the status quo.  This represents the best the industry has to offer and we are excited to be nominated alongside other innovative companies in the bioprocess industry.  The …

Upcoming Event: Boston Biotech Week 2016

We are happy to announce our attendance at the Cell and Gene Therapy Bioprocessing meeting during Boston Biotech Week, October 5-7, 2016.  Visit our team at Booth #1446 learn how MagCloudz cell isolation kits and methods yield highly viable cells for downstream research.

Quad Technologies: Launching a New Era in Cell Separation

Cell separation technologies and products from Quad Technologies address two of the greatest challenges in the advancement of cellular immune therapies today:  1) successfully and rapidly separating cells in the laboratory without threatening their viability, and 2) translating that success to a greater scale in clinical manufacturing applications. The company’s work is ushering in a new generation in cell separation that …

Quad Technologies Awarded a National Science Foundation STTR Phase I Grant

    Quad Technologies has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant to support research and development efforts addressing critical challenges associated with clinical cell processing.   The grant will support development of an Affinity Chromatographic Cell Sorting (AFFICS) System for sorting of multiple cell types from a heterogeneous mixture without the use …

Development of a Novel Cell-Separation Platform: Discussion with Quad Technologies CEO Sean Kevlahan

Releasing and separating cells from surfaces and capture molecules are critical steps in cell therapy development. Research into such therapies as chimeric antigen receptor T cells (CAR-T) cancer therapies and stem-cell regenerative medicines demand the isolation and purification of viable and functional target cells. A number of cell-separation strategies can be used to produce such cells, but they are not …

Overcoming the Roadblocks to Successful T-Cell Isolation

New Method for High-Efficiency Capture and Label-Free Release of High-Purity Target Cell Populations Cell-based therapeutics, such as CAR-T cancer therapies, are poised to transform 21st century medical care. These innovative medicines require highly specific isolation and purification of large numbers of viable, functional cells, a process that is often technically complex and cost-prohibitive. Consequently, demand is growing for novel approaches …

Novel Hydrogel-Based Approach for Cell Isolation, Purification and Release

The purification and enrichment of specific cell populations from complex starting samples is a critical component of multiple life science workflows. While the key objective of most protocols is to obtain a highly pure and viable population of cells for downstream applications and analysis, most do not meet this goal. Issues with conventional cell separation methods, such as traditional magnetic …

Quad Technologies Collaborates with University of Massachusetts Medical School to Highlight Benefits of Novel Cell Separation Solution

WOBURN, Mass.–(BUSINESS WIRE)–The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery. Quad Technologies (“Quad”), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with the University of Massachusetts Medical School to evaluate the …

MagCloudz Streptavidin Cell Separation Kit

Quad Technologies Launches Fully Releasable Cell Separation Solution for Enhanced Cell Purity and Viability Following Successful Investment Round

WOBURN, Mass.–(BUSINESS WIRE)–The most promising areas of translational medical research, including CAR-T cancer therapies and stem cell-based regenerative medicine, require the isolation and purification of large numbers of viable, functional cells. There is growing demand from researchers and clinicians for technologies that provide high viability, enhanced efficiency and scalability to optimize conventional cell separation techniques. Read More…